Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Martin Hoyle Chris Cooper |
| Publication date | January 23, 2013 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |